The Experts below are selected from a list of 3 Experts worldwide ranked by ideXlab platform

De Rosa - One of the best experts on this subject based on the ideXlab platform.

  • Oral Bisoprolol for the treatment of non-resolving central serous chorioretinopathy: A case report
    2020
    Co-Authors: Napolitano G, Rigoni E, De Rosa
    Abstract:

    Purpose: To evaluate the effect of the beta blocker Bisoprolol in the treatment of chronic central serous chorioretinopathy (CSC).Methods: Five patients with non-resolving CSC were treated with oral Bisoprolol 2,5 mg once a day for three months. The best-corrected visual acuity (BCVA), central macular thickness (CMT) and sub-Retinal fluid (SRF) horizontal diameter recorded at baseline and at 1, 2, and 3 months by optical coherence tomography (OCT) were analyzed.Results: All the patients achieved a full visual recovery after 3 months of treatment and there was no evidence of SRF at the last OCT follow-up. No side effect was recorded.Conclusions: These results suggest that oral Bisoprolol may be effective in the treatment of chronic CSC and could be considered as a potential therapy choice in those cases at risk of diffuse Retina Pigment Epitheliopathy.

Napolitano G - One of the best experts on this subject based on the ideXlab platform.

  • Oral Bisoprolol for the treatment of non-resolving central serous chorioretinopathy: A case report
    2020
    Co-Authors: Napolitano G, Rigoni E, De Rosa
    Abstract:

    Purpose: To evaluate the effect of the beta blocker Bisoprolol in the treatment of chronic central serous chorioretinopathy (CSC).Methods: Five patients with non-resolving CSC were treated with oral Bisoprolol 2,5 mg once a day for three months. The best-corrected visual acuity (BCVA), central macular thickness (CMT) and sub-Retinal fluid (SRF) horizontal diameter recorded at baseline and at 1, 2, and 3 months by optical coherence tomography (OCT) were analyzed.Results: All the patients achieved a full visual recovery after 3 months of treatment and there was no evidence of SRF at the last OCT follow-up. No side effect was recorded.Conclusions: These results suggest that oral Bisoprolol may be effective in the treatment of chronic CSC and could be considered as a potential therapy choice in those cases at risk of diffuse Retina Pigment Epitheliopathy.

Rigoni E - One of the best experts on this subject based on the ideXlab platform.

  • Oral Bisoprolol for the treatment of non-resolving central serous chorioretinopathy: A case report
    2020
    Co-Authors: Napolitano G, Rigoni E, De Rosa
    Abstract:

    Purpose: To evaluate the effect of the beta blocker Bisoprolol in the treatment of chronic central serous chorioretinopathy (CSC).Methods: Five patients with non-resolving CSC were treated with oral Bisoprolol 2,5 mg once a day for three months. The best-corrected visual acuity (BCVA), central macular thickness (CMT) and sub-Retinal fluid (SRF) horizontal diameter recorded at baseline and at 1, 2, and 3 months by optical coherence tomography (OCT) were analyzed.Results: All the patients achieved a full visual recovery after 3 months of treatment and there was no evidence of SRF at the last OCT follow-up. No side effect was recorded.Conclusions: These results suggest that oral Bisoprolol may be effective in the treatment of chronic CSC and could be considered as a potential therapy choice in those cases at risk of diffuse Retina Pigment Epitheliopathy.